skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8129

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis

Review

(2176) Views  (594) Full article downloads

Authors: Melissa A Michelon, Alice B Gottlieb

Published Date May 2010 Volume 2010:3 Pages 79 - 84
DOI: http://dx.doi.org/10.2147/CCID.S6186

Melissa A Michelon1, Alice B Gottlieb1,2

1Tufts University School of Medicine, 2Department of Dermatology, Tufts Medical Center, Boston, MA, USA

Abstract: Psoriatic arthritis (PsA) is an inflammatory arthritis that affects many psoriasis patients and can often have a debilitating disease progression. Golimumab is a new tumor necrosis factor (TNF) antagonist recently approved by the FDA for controlling signs and symptoms of psoriatic arthritis. In a Phase III clinical trial in patients with PsA, patients receiving golimumab showed significant improvement in the signs and symptoms of disease. It was usually well tolerated, but adverse events generally occurred more in patients receiving golimumab compared to placebo. Golimumab has also recently shown efficacy in slowing structural damage in PsA. This new biologic therapy provides physicians with another option in the treatment of this inflammatory arthritis while offering patients certain advantages over other TNF antagonists.

Keywords: golimumab, psoriatic arthritis, TNF-alpha inhibitor
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • American Acne and Rosacea Society

    The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.